Jean-Marc Chapplain

557 total citations
16 papers, 231 citations indexed

About

Jean-Marc Chapplain is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Jean-Marc Chapplain has authored 16 papers receiving a total of 231 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Infectious Diseases, 7 papers in Virology and 5 papers in Epidemiology. Recurrent topics in Jean-Marc Chapplain's work include HIV Research and Treatment (7 papers), HIV/AIDS drug development and treatment (6 papers) and HIV/AIDS Research and Interventions (4 papers). Jean-Marc Chapplain is often cited by papers focused on HIV Research and Treatment (7 papers), HIV/AIDS drug development and treatment (6 papers) and HIV/AIDS Research and Interventions (4 papers). Jean-Marc Chapplain collaborates with scholars based in France, Belgium and Liberia. Jean-Marc Chapplain's co-authors include C. Michelet, C. Arvieux, Pierre Tattevin, Olivier Tribut, Danièle Bentué‐Ferrer, H. Allain, Yazdan Yazdanpanah, Faouzi Souala, Hélène Leroy and Matthieu Revest and has published in prestigious journals such as Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy and Critical Care Medicine.

In The Last Decade

Jean-Marc Chapplain

16 papers receiving 227 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jean-Marc Chapplain France 10 156 92 59 40 27 16 231
Nang Thu Thu Kyaw Myanmar 12 322 2.1× 91 1.0× 195 3.3× 69 1.7× 36 1.3× 40 405
Neena Bodasing United Kingdom 7 174 1.1× 66 0.7× 96 1.6× 44 1.1× 22 0.8× 15 269
Christopher KC Lee Malaysia 11 258 1.7× 129 1.4× 115 1.9× 77 1.9× 12 0.4× 23 347
Ken Ho United States 11 186 1.2× 39 0.4× 126 2.1× 89 2.2× 21 0.8× 42 316
Maria Letícia Santos Cruz Brazil 11 152 1.0× 71 0.8× 100 1.7× 57 1.4× 41 1.5× 24 301
Jurai Wongsawat Thailand 11 208 1.3× 108 1.2× 57 1.0× 95 2.4× 50 1.9× 30 339
Christelle Meuris Belgium 9 105 0.7× 40 0.4× 131 2.2× 39 1.0× 7 0.3× 21 240
Sujit Suchindran United States 8 239 1.5× 35 0.4× 214 3.6× 82 2.0× 12 0.4× 19 385
Herry Mapesi Tanzania 9 139 0.9× 49 0.5× 80 1.4× 45 1.1× 16 0.6× 23 198
Heloísa Ramos Lacerda Brazil 13 269 1.7× 128 1.4× 145 2.5× 77 1.9× 16 0.6× 42 414

Countries citing papers authored by Jean-Marc Chapplain

Since Specialization
Citations

This map shows the geographic impact of Jean-Marc Chapplain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean-Marc Chapplain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean-Marc Chapplain more than expected).

Fields of papers citing papers by Jean-Marc Chapplain

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean-Marc Chapplain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean-Marc Chapplain. The network helps show where Jean-Marc Chapplain may publish in the future.

Co-authorship network of co-authors of Jean-Marc Chapplain

This figure shows the co-authorship network connecting the top 25 collaborators of Jean-Marc Chapplain. A scholar is included among the top collaborators of Jean-Marc Chapplain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean-Marc Chapplain. Jean-Marc Chapplain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Bot, Audrey Le, R. Lecomte, François Bénézit, et al.. (2020). Is Rifampin Use Associated With Better Outcome in Staphylococcal Prosthetic Valve Endocarditis? A Multicenter Retrospective Study. Clinical Infectious Diseases. 72(9). e249–e255. 17 indexed citations
2.
Tattevin, Pierre, G Raguin, Jean-Marc Chapplain, et al.. (2015). Retention in care for HIV-infected patients in the eye of the Ebola storm. AIDS. 29(6). N1–N2. 18 indexed citations
3.
Loubet, Paul, Jean-Marc Chapplain, Nathalie Cartier, et al.. (2015). Likely effect of the 2014 Ebola epidemic on HIV care in Liberia. AIDS. 29(17). 2347–2351. 19 indexed citations
4.
5.
6.
Loubet, Paul, Charlotte Charpentier, Benoît Visseaux, et al.. (2015). Prevalence of HIV-1 drug resistance among patients failing first-line ART in Monrovia, Liberia: a cross-sectional study. Journal of Antimicrobial Chemotherapy. 70(6). 1881–1884. 14 indexed citations
7.
Loubet, Paul, Charlotte Charpentier, Benoît Visseaux, et al.. (2014). Short Communication: Prevalence of HIV-1 Transmitted Drug Resistance in Liberia. AIDS Research and Human Retroviruses. 30(9). 863–866. 8 indexed citations
8.
Chapplain, Jean-Marc, Pierre Tattevin, Hélène Leroy, et al.. (2014). Prevalence of and risk factors for acute mountain sickness among a cohort of high-altitude travellers who received pre-travel counselling. Travel Medicine and Infectious Disease. 12(5). 534–540. 17 indexed citations
9.
Chapplain, Jean-Marc, Éric Bellissant, Dominique Guyader, et al.. (2013). The effects of a maintenance therapy with peg-interferon alpha-2a on liver fibrosis in HIV/HCV co-infected patients: A randomized controlled trial. Journal of Infection. 67(4). 313–321. 4 indexed citations
10.
11.
Chapplain, Jean-Marc, Pierre Tattevin, Dominique Guyader, et al.. (2011). Mitochondrial Abnormalities in Patients with HIV-HCV Co-infection as Compared to Patients with HCV Mono-infection. HIV Clinical Trials. 12(1). 54–60. 6 indexed citations
12.
Maillard, Anne, Jean-Marc Chapplain, Olivier Tribut, et al.. (2007). The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir–ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Journal of Clinical Virology. 38(2). 131–138. 13 indexed citations
13.
Chapplain, Jean-Marc, J. Beillot, Jean‐Marc Bégué, et al.. (2004). Mitochondrial Abnormalities in HIV-Infected Lipoatrophic Patients Treated With Antiretroviral Agents. JAIDS Journal of Acquired Immune Deficiency Syndromes. 37(4). 1477–1488. 24 indexed citations
14.
Arvieux, C., Pierre Tattevin, Faouzi Souala, et al.. (2002). Salvage therapy with amprenavir and ritonavir: Prospective study in 17 heavily pretreated patients. HIV Clinical Trials. 3(2). 125–132. 11 indexed citations
15.
16.
Michelet, C., Annick Ruffault, Véronique Sebille, et al.. (2001). Ritonavir-Saquinavir Dual Protease Inhibitor Compared to Ritonavir Alone in Human Immunodeficiency Virus-Infected Patients. Antimicrobial Agents and Chemotherapy. 45(12). 3393–3402. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nang Thu Thu Kyaw Breakdown of academic impact, for papers by Neena Bodasing Breakdown of academic impact, for papers by Christopher KC Lee Breakdown of academic impact, for papers by Ken Ho Breakdown of academic impact, for papers by Maria Letícia Santos Cruz Breakdown of academic impact, for papers by Jurai Wongsawat Breakdown of academic impact, for papers by Christelle Meuris Breakdown of academic impact, for papers by Sujit Suchindran Breakdown of academic impact, for papers by Herry Mapesi Breakdown of academic impact, for papers by Heloísa Ramos Lacerda
Rankless by CCL
2026